SC Filed 2022-11-28 Event — SEC 0001072613-22-000649 →

Growth Equity Opportunities Fund IV, LLC → Addex Therapeutics Ltd. ADXN

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 11/100

Passive Schedule 13G filer baseline
Short interest building (+205.1% vs prior settlement)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

7 13D/G filings on this issuer

6 other filings besides this one

Filer Track Record

10 filings by this filer

9 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 1.00

5,613 shares short · +205.1% vs prior

Other 13D/G Filings on Addex Therapeutics Ltd.

Filed	Form	Filer	Stake	Shares
2026-09-04	SCHEDULE 13D/A	Dyer Timothy Mark	9.01%	19,165,714	view →
2026-08-27	SCHEDULE 13D/A	Dyer Timothy Mark	8.98%	19,095,510	view →
2023-04-05	SC	Dyer Timothy Mark	—	—	view →
2022-08-05	SC	Dyer Timothy Mark	—	—	view →
2022-01-10	SC	Growth Equity Opportunities Fund IV, LLC	—	—	view →
2021-09-08	SC	Dyer Timothy Mark	—	—	view →

Other Filings by Growth Equity Opportunities Fund IV, LLC

Filed	Form	Issuer	Stake	Shares
2025-01-21	SCHEDULE	Verona Pharma plc	4.99%	32,679,649	view →
2022-01-10	SC	Addex Therapeutics Ltd. ADXN	—	—	view →
2021-04-21	SC	Affimed N.V.	—	—	view →
2020-08-03	SC	Verona Pharma plc	—	—	view →
2020-06-24	SC	AVEO PHARMACEUTICALS, INC.	—	—	view →
2019-04-17	SC	AVEO PHARMACEUTICALS INC	—	—	view →
2018-07-10	SC	AVEO PHARMACEUTICALS INC	—	—	view →
2018-03-19	SC	Cascadian Therapeutics, Inc.	—	—	view →
2018-03-05	SC	ARCA biopharma, Inc. ORKA	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →